Clinical Trials
31 trialsPETRA
AstraZeneca
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
IVY
Eli Lilly and Company
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Eastern Cooperative Oncology Group
Trial of NanoPac Focal Therapy for Prostate Cancer
NanOlogy, LLC
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Jonsson Comprehensive Cancer Center
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
University of Maryland, Baltimore
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
NanOlogy, LLC
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
M.D. Anderson Cancer Center
Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer
NYU Langone Health
Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
George Washington University
Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
Weill Medical College of Cornell University
Lenalidomide and Paclitaxel in Prostate Cancer
M.D. Anderson Cancer Center
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Alliance for Clinical Trials in Oncology
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate
University of Michigan Rogel Cancer Center
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
University of California, San Francisco
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
SWOG Cancer Research Network
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer
Fox Chase Cancer Center
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
Memorial Sloan Kettering Cancer Center
Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NYU Langone Health
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
GlaxoSmithKline
Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma
M.D. Anderson Cancer Center
Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
Rutgers, The State University of New Jersey
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
SCRI Development Innovations, LLC